Su Dr. Marco Merlano

Merlano Marco, nato a Genova, 8 maggio 1953, residente a Cuneo,

Struttura di Appartenenza: SC Oncologia Medica, AO S. Croce e Carle, Cuneo

Curriculum professionale

1981: Specializzazione in Oncologia, Università di Genova.

1980-1990: Assistente e 1990-1995: Aiuto, Oncologia Medica Istituto Nazionale per la Ricerca sul Cancro, Genova.

Attualmente: Primario, Oncologia Medica, e Direttore Dipartimento Medicina Specialistica AO S. Croce e Carle, Cuneo, Direttore del Polo Oncologico di Cuneo.

Training formativi per attività clinica e di ricerca: Sidney Farber Cancer Institute, Harvard Medical School, Boston, USA; Radiobiologia e Biofisica, Università della  Virginia, Charlottesville, USA; Medical Oncology, Rush Presbyterian School of Medicine, Chicago, USA.

Membro di Società Scientifiche: Associazione Italiana di Oncologia Medica, referring member dell’Organizzazione Europea per la Ricerca sulle Terapie per il Cancro (E.O.R.T.C.); European Society of Medical Oncology, membro onorario New England Cancer Society, American Society of Medical Oncology.




Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Oncotarget. 2016 Mar 28. doi: 10.18632/oncotarget.8417. [Epub ahead of print]


Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC. 

Int J Biol Markers. 2016 Mar 22:0. doi: 10.5301/jbm.5000193. [Epub ahead of print]


Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.

Anticancer Drugs. 2016 Mar 15. [Epub ahead of print]


Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.

Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.

Laryngoscope. 2015 Nov 24. doi: 10.1002/lary.25754. [Epub ahead of print]


p16 cut-off in Head and Neck Squamous Cell Carcinoma (HNSCC): correlation among tumour and patients characteristics and outcome

International Journal of Biological Markers Merlano MC , Denaro N , Vivenza D, Monteverde M, Russi E, Lerda W, Comino A, Lo Nigro C   BACKGROUND p16 is has been indicated as a suitable surrogate biomarker of HPV infection. Prognosis of p16 positive (pos) SCC oropharynx tumour (OT) is better than p16 neg. METHODS We analyzed 209 samples of SCCHN, to establish a predictive p16 cut-off and its role in OT/non-OT. We compared the outcome of tumours harbouring any percentage of p16 pos cells (≥ 1%) with negative (neg) ones. Then we considered three cut-offs (10%, 50% and 70% pos cells) to evaluate the outcome of OT/non-OT with similar p16 expression and p16pos vs. neg tumours stratified by age. RESULTS p16neg in OT/non-OT were 29/49% respectively (p=0.0054). The cumulative distribution showed that the pos values were located around two focus points: 2% and 96%. The subgroup analysis showed that only OT occurred in young patients (<65y.o.) and with p16 positive cells ≥70% gain in better survival. CONCLUSIONS p16 positivity impacts the outcome only among young patients and in OT (p=0.048).


Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, Granetto C, Occelli M, Fea E, Heouaine A, Gasco M, Merlano M.

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005 Mar 1;103(5):994-9


Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol. 2010 Nov;37(5):1219-28


Denaro N, Lo Nigro C, Natoli G, Russi EG, Adamo V, Merlano MC.

The Role of p53 and MDM2 in Head and Neck Cancer. Otolaryngol 2011 Dec 7;2011:931813


Numico G, Occelli M, Russi EG, Silvestris N, Pasero R, Fea E, Granetto C, Di Costanzo G, Colantonio I, Gasco M, Garrone O, Polla V, Merlano MC.

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Support Care Cancer 2011 Nov;19(11):1823-30


Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol 2013 Nov;31(8):1567-75


Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.

Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer 2012 Aug 7;107(4):732-8


Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol 2013 May;133(5):1278-85


Russi EG, Numico G, Merlano MC.

Nonsurgical conservative approach for laryngeal cancer: what information should patients be given? J Clin Oncol 2013 Sep 1;31(25):3168-70


Denaro N, Russi EG, Lefebvre JL, Merlano MC.

 A systematic review of current and emerging approaches in the field of larynx preservation Radiother Oncol. 2013 Oct 15


de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C.

LIFE Study Team. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. Clin Lung Cancer. 2014 Sep;15(5):338-45.


Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G.

Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014 Sep;19(9):966-74


There is no event available.

Ask a Question

Contact Info